Zimbabwe: Zimbabwe Is the First Country in Africa to Announce Regulatory Approval for Long-Acting Injectable Cabotegravir for HIV Prevention

[WHO] The Medicines Control Authority of Zimbabwe (MCAZ) announced that it has approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention.
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news